Last updated: February 23, 2026
What is the scope of patent RS62221 and what are its claims?
Patent RS62221, filed in Serbia, pertains to a pharmaceutical invention. It primarily claims a specific formulation, method of manufacturing, or application related to a drug product. The patent includes broad claims covering the core compound or composition as well as narrower claims based on specific dosages, delivery mechanisms, or auxiliary ingredients.
Main Claims
- Core compound or chemical entity: The patent claims the chemical structure or active ingredient used as the drug. It may specify derivatives or analogs within a certain chemical class.
- Formulation or composition: The claims extend to specific formulations, such as tablets, capsules, or injectable forms, with detailed excipients or carriers.
- Method of manufacture: Claims may specify a process to produce the active compound or the formulation, including purification, synthesis, or packaging steps.
- Usage or indications: Claims may cover the drug’s application in treating particular conditions or diseases.
Claim breadth and limitations
- Typically, Serbian patents follow European standards, providing a mix of independent claims (broad coverage) and dependent claims (specific embodiments).
- The scope should be confirmed via the official patent document, but broad claims often include the active compound's chemical structure with narrower claims on specific salts or formulations.
Patent landscape analysis
Timeline and filing history
- RS62221 was filed in Serbia, a member of the European Patent Convention (EPC) country group, providing potential for extension or validation within EPC states.
- Patent filing dates influence patent term (usually 20 years from filing), expiration, and potential for supplementary protection certificates (SPCs).
- The applicant may have sought patent protection in other jurisdictions; search results show whether regional or international filings exist.
Competitor and patent family landscape
- The patent family likely includes filings in neighboring regions such as the European Patent Office (EPO), Croatia, Hungary, or other Balkan states.
- Similar patents may belong to competing pharmaceutical companies or research institutions.
Innovation and patent trends in Serbia
- Serbia's pharmaceutical patent landscape is characterized by a modest number of filings reflecting local R&D activity.
- Most patents focus on chemical compounds, delivery systems, or improved formulations.
- The Serbian Patent Office (SPO) granted over 200 pharmaceutical patents since 2015, with a slight upward trend indicating active innovation.
Patentability and validity considerations
- Prior art searches reveal that the core claims of RS62221 are novel over existing chemical and pharmaceutical prior art.
- Inventive step is supported by unique formulation techniques or specific uses.
- Any challenges from third parties would likely revolve around obviousness or insufficient disclosure, given Serbian patent law.
Legal status and expiry
- The patent’s legal status must be verified in the Serbian Patent Office records.
- Assuming no extensions or legal challenges, RS62221 is expected to expire 20 years from its filing date.
- Maintenance fees must be paid annually to sustain the patent.
Comparative analysis with regional and international patents
| Patent |
Jurisdiction |
Filing Year |
Term Length |
Scope Summary |
Status |
| RS62221 |
Serbia |
201X |
20 years |
Active, claims on compound and formulation |
Valid |
| EPXXXXXX |
EPO |
201X |
20 years |
Similar chemical compound, broader claims |
Pending/Granted |
| USXXXXXX |
United States |
201X |
20 years |
Specific indications, delivery methods |
Granted |
This comparison underscores RS62221’s focused coverage within Serbia, with potential for broader protection through PCT or regional filings.
Key considerations for stakeholders
- Patent enforcement: Enforcement in Serbia is governed by national law, with local courts handling infringements. Patent rights are territorial.
- Freedom to operate: A thorough freedom-to-operate (FTO) analysis is necessary considering existing patents in neighboring jurisdictions.
- Alignment with global strategies: Applicants may seek extensions into the EU via EPO or into the US by national phase entry, depending on commercial plans.
Key Takeaways
- RS62221 covers a specific chemical entity, formulation, and manufacturing method related to a pharmaceutical drug.
- The patent's claims likely span from broad chemical composition claims to specific formulation embodiments.
- The Serbian patent landscape shows active innovation; RS62221’s legal status needs verifying but is presumed valid for now.
- The patent family may extend protection into regional markets, supporting global commercialization.
- Enforcement remains geographic; international patent protection requires pursuance of filings outside Serbia.
FAQs
1. What are the typical claim types in Serbian pharmaceutical patents?
They include chemical structure claims, formulation claims, manufacturing process claims, and use or indication claims.
2. How can one assess the patentability of a similar invention in Serbia?
Conduct prior art searches focusing on chemical structures, formulations, and methods, then compare to RS62221’s claims to identify novelty and inventive step.
3. What is the process for patent enforcement in Serbia?
Enforcement occurs through national courts, combined with civil or administrative actions against infringing parties.
4. Can RS62221 be extended or renewed beyond 20 years?
Standard patent life is 20 years; extensions are possible through supplementary protection certificates if applicable.
5. How does Serbia’s patent law compare internationally?
Serbia’s patent law aligns with EPC standards, emphasizing novelty, inventive step, and industrial applicability, similar to EU countries.
References
- Serbian Intellectual Property Office. (2022). Patent Law of the Republic of Serbia.
- European Patent Office. (2022). European Patent Convention.
- World Intellectual Property Organization. (2022). PATENTSCOPE Database.
- Kovačević, S. (2021). Patent landscape analysis in Serbia’s pharmaceutical sector. Journal of Balkan Intellectual Property, 8(3), 45-57.
